Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Soria, J.-C.
Right arrow Articles by Le Chevalier, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soria, J.-C.
Right arrow Articles by Le Chevalier, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1515-1517, 2002
© 2002 European Society for Medical Oncology

Editorial

Is cisplatin still the best platinum compound in non-small-cell lung cancer?

J.-C. Soria and T. Le Chevalier

Institut Gustave Roussy, 39, rue Camille Desmoulins, F-94805 Villejuif Cedex, France (E-mail: tle-che@igr.fr)

The first 150 words of the full text of this article appear below.

Lung cancer remains the leading cause of cancer-related death in industrialized countries and is therefore a major health problem for western societies [1]. In the past, the role of chemotherapy for non-small-cell lung cancer (NSCLC) has been extensively debated and the lack of activity of most cytotoxic compounds, used as single agents or in combination, led a large part of the medical community to refute chemotherapy for patients with NSCLC. Nevertheless, anecdotical reports and occasional prospective studies suggested a potential benefit of chemotherapy in advanced NSCLC in the 1970s.

In fact, the era of chemotherapy in NSCLC began with the introduction of cisplatin in this setting, despite studies suggesting a poorly encouraging activity/toxicity ratio [2]. First generation phase III studies using cisplatin-based doublets reported encouraging and sometimes statistically significant survival benefits when compared with best supportive care (BSC) [3]. However, it took almost 20 . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
A. Ardizzoni, L. Boni, M. Tiseo, F. V. Fossella, J. H. Schiller, M. Paesmans, D. Radosavljevic, A. Paccagnella, P. Zatloukal, P. Mazzanti, et al.
Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis
J Natl Cancer Inst, June 6, 2007; 99(11): 847 - 857.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol PractHome page
M. R. Green, M. Andrews, R. Leff, J. Willey, C. Allegra, A. Denes, J. Epstein, J. Jones, and L. Lokey
Adjuvant Therapy Choices in Patients With Resected Non-Small-Cell Lung Cancer: Correlation of Doctors' Treatment Plans and Relevant Phase III Trial Data
J. Oncol. Pract, July 1, 2005; 1(2): 37 - 42.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. Winton, R. Livingston, D. Johnson, J. Rigas, M. Johnston, C. Butts, Y. Cormier, G. Goss, R. Inculet, E. Vallieres, et al.
Vinorelbine plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer
N. Engl. J. Med., June 23, 2005; 352(25): 2589 - 2597.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. Delbaldo, S. Michiels, N. Syz, J.-C. Soria, T. Le Chevalier, and J.-P. Pignon
Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer: A Meta-analysis
JAMA, July 28, 2004; 292(4): 470 - 484.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Kerr
A little citadel of light in a malignant sea of darkness
Ann. Onc., January 1, 2004; 15(1): 1 - 2.
[Full Text] [PDF]